Lisanti Capital Growth LLC Sells 156,665 Shares of Adaptive Biotechnologies Corporation $ADPT

Lisanti Capital Growth LLC trimmed its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 52.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 142,515 shares of the company’s stock after selling 156,665 shares during the period. Lisanti Capital Growth LLC’s holdings in Adaptive Biotechnologies were worth $2,314,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Ameriprise Financial Inc. lifted its stake in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Aristotle Atlantic Partners LLC lifted its stake in shares of Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after buying an additional 247,402 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Adaptive Biotechnologies by 103.9% in the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after buying an additional 1,363,181 shares during the last quarter. Fred Alger Management LLC lifted its stake in shares of Adaptive Biotechnologies by 6.7% in the third quarter. Fred Alger Management LLC now owns 2,514,234 shares of the company’s stock worth $37,613,000 after buying an additional 158,807 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after buying an additional 2,062,282 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ADPT shares. TD Cowen upped their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Morgan Stanley cut their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Finally, BTIG Research restated a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Stock Up 0.1%

Shares of NASDAQ:ADPT opened at $13.88 on Friday. Adaptive Biotechnologies Corporation has a 12 month low of $8.50 and a 12 month high of $20.76. The company’s 50-day moving average price is $13.79 and its two-hundred day moving average price is $15.62. The firm has a market cap of $2.22 billion, a P/E ratio of -42.06 and a beta of 2.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same quarter in the prior year, the firm earned ($0.20) EPS. The company’s revenue was up 35.1% on a year-over-year basis. As a group, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, CFO Kyle Piskel sold 3,115 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $13.04, for a total transaction of $40,619.60. Following the sale, the chief financial officer owned 256,725 shares of the company’s stock, valued at $3,347,694. This represents a 1.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Chad M. Robins sold 37,263 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $15.19, for a total transaction of $566,024.97. Following the completion of the transaction, the chief executive officer directly owned 2,180,518 shares in the company, valued at $33,122,068.42. This trade represents a 1.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,420,283 shares of company stock valued at $34,193,619 in the last 90 days. 5.70% of the stock is currently owned by insiders.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.